| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/12/2000 | EP0991402A1 Poly(vinyl alcohol) cryogel |
| 04/12/2000 | EP0799026B1 Hemolysis prevention by surfactants |
| 04/12/2000 | EP0785776B1 Preparation of protein microspheres, films and coatings |
| 04/12/2000 | CN1250378A Pharmaceutical compositions |
| 04/12/2000 | CN1250377A Hydrophilic binary systems for the administration of cyclosporine |
| 04/12/2000 | CN1250372A Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
| 04/12/2000 | CN1250370A Aqueous suspension for nasal administration of loteprednol |
| 04/12/2000 | CN1250369A Method of treating dry eye disease with purinergic receptor agonists |
| 04/12/2000 | CN1249951A Coated aquocomposition and method for preparing solid medicine |
| 04/12/2000 | CN1249950A Preparation of pharmaceutical active granules |
| 04/12/2000 | CN1249934A Thermal stabilized antiacid and deaired suspensoid agent |
| 04/12/2000 | CN1051331C Process for producing stable magnesium hydroxide slurries |
| 04/12/2000 | CN1051228C Novel medical composition containing hyaluronic acid associates and its preparing process |
| 04/12/2000 | CN1051225C Stable gastric acid tolerance-Omeprazole microgranules composition and its preparation method |
| 04/11/2000 | US6048967 Blood compound associated with a nitroxide compound to prevent or alleviate the side effects of oxygen stress |
| 04/11/2000 | US6048908 Hydrophilic polymeric material |
| 04/11/2000 | US6048874 Parenteral metolazone formulations |
| 04/11/2000 | US6048851 Solid pharmaceutical compositions for the oral administration of gallium |
| 04/11/2000 | US6048845 Antiulcer agent; mixture of cyclodextri ad cytotoxic drug |
| 04/11/2000 | US6048844 Treatment of conditions and disease |
| 04/11/2000 | US6048736 Producing a controlled drug delivery system; mixing polymers with a variety of compounds, cross-linking the polymers with biocompatible cleavage sites, incubate with compound which activates controlled release |
| 04/11/2000 | US6048729 Animal transfected clonal cells for the expression of therapeutic products |
| 04/11/2000 | US6048724 Producing mammalian transfected cell strain which expresses exogenous dna encoding erythropoietin and glucagons; for prevention or treatment of a condition in which insulin production or glucagon function is defective |
| 04/11/2000 | US6048720 Conjugates of a polypeptide and a biocompatible polymer |
| 04/11/2000 | US6048553 Aqueous metal bicarbonate solution useful in treating inflammatory, degenerative and viral diseases |
| 04/11/2000 | US6048552 DASC compositions, process for preparing same and suspensions containing same |
| 04/11/2000 | US6048548 Sustained release heterodisperse hydrogel systems-amorphous drugs |
| 04/11/2000 | US6048541 Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| 04/11/2000 | US6048536 Vaccine compositions |
| 04/11/2000 | US6048531 Immunogenic composites capable of stimulating production of anti-peptide antibodies, pharmaceutical compositions employing these composites and methods of selectively inducing production of anti-peptide antibodies |
| 04/11/2000 | US6048530 Inducing cytotoxic t-cell response against viruses, bacteria, fungi, and parasites; immunology |
| 04/11/2000 | US6048529 PVA or PEG conjugates of peptides for epitope-specific immunosuppression |
| 04/11/2000 | US6048528 Monoclonal antibody for diagnostic and therapeutic use in ovarian cancer |
| 04/11/2000 | US6048524 In vivo production and delivery of erythropoietin for gene therapy |
| 04/11/2000 | US6048522 Heterogeneous vinyl polymer in silicone oil solvent; oil in water emulsions |
| 04/11/2000 | US6048515 Iron-containing nanoparticles with double coating and their use in diagnosis and therapy |
| 04/11/2000 | CA2182086C Use of mometasone furoate for treating airway passage and lung diseases |
| 04/11/2000 | CA1340958C Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines |
| 04/11/2000 | CA1340956C Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines |
| 04/06/2000 | WO2000018949A2 Delivery of phosphoinositide polyphosphates into cells |
| 04/06/2000 | WO2000018821A1 Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties |
| 04/06/2000 | WO2000018468A1 Method, device and kit for performing gene therapy |
| 04/06/2000 | WO2000018440A1 Somatostatin receptor radioligand with increased uptake |
| 04/06/2000 | WO2000018423A1 Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues |
| 04/06/2000 | WO2000018406A1 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid |
| 04/06/2000 | WO2000018401A1 Antimycotic drug composition |
| 04/06/2000 | WO2000018397A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same |
| 04/06/2000 | WO2000018377A1 Enteric and colonic delivery using hpmc capsules |
| 04/06/2000 | WO2000018376A1 Aqueous enteric coating composition with low gastric permeability |
| 04/06/2000 | WO2000018375A1 Application of water-soluble or water-dispersible polymerizates which contain poly-ether and which are used as a coating agent, a binding agent and/or as a film-forming auxiliary agent in pharmaceutical forms of administration |
| 04/06/2000 | WO2000018374A1 Controlled release nanoparticulate compositions |
| 04/06/2000 | WO2000018373A1 Core tablet for controlled release of gliclazide after oral administration |
| 04/06/2000 | WO2000018371A1 Proteinic drug delivery system using membrane mimetics |
| 04/06/2000 | WO2000018370A2 Liquid pharmaceutical for oral delivery |
| 04/06/2000 | WO2000018369A1 Iontophoretic devices comprising piperidin derivatives |
| 04/06/2000 | WO2000018365A2 Fast dissolving orally consumable films |
| 04/06/2000 | WO2000018339A1 Methods and apparatus for improved administration of pharmaceutically active compounds |
| 04/06/2000 | WO2000018336A1 Targeted therapy to a biomedical device |
| 04/06/2000 | WO2000018331A2 Drug delivery systems |
| 04/06/2000 | WO2000018316A2 Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
| 04/06/2000 | WO2000018259A1 Nutritional and pharmaceutical compositions |
| 04/06/2000 | WO2000018254A2 Method of protecting heat- or oxygen-labile compounds to preserve activity and bioavailability |
| 04/06/2000 | WO1999067284A3 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 04/06/2000 | WO1999065452A3 Hydrogels of water soluble polymers crosslinked by protein domains |
| 04/06/2000 | WO1999062510A3 Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases |
| 04/06/2000 | WO1999055730A3 Polyepitope carrier protein |
| 04/06/2000 | WO1999052858A3 Lipids |
| 04/06/2000 | WO1999046284A3 Molecules that home to various selected organs or tissues |
| 04/06/2000 | WO1999040113A3 Lipopeptides containing an interferon fragment and uses thereof in pharmaceutical compositions |
| 04/06/2000 | WO1999037294A3 Mitochondria protecting agents for treating mitochondria associated diseases |
| 04/06/2000 | DE19845358A1 Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe Excessive dosage forms with controlled release |
| 04/06/2000 | DE19844903A1 Use of water-soluble and water-dispersible polyalkylene oxide and polyglycerol containing polymerizates as pharmaceutical coating agents, binders and film-formers |
| 04/06/2000 | CA2345988A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same |
| 04/06/2000 | CA2345638A1 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid |
| 04/06/2000 | CA2345612A1 Anti-fungal composition |
| 04/06/2000 | CA2345532A1 Delivery of phosphoinositide polyphosphates into cells |
| 04/06/2000 | CA2345306A1 Nutritional and pharmaceutical compositions |
| 04/06/2000 | CA2345075A1 Mixed liposome drug delivery system using membrane mimetics |
| 04/06/2000 | CA2341489A1 Somatostatin receptor radioligand with increased uptake |
| 04/06/2000 | CA2340130A1 Liquid pharmaceutical for oral delivery |
| 04/06/2000 | CA2249675A1 A novel composition containing cyclosporin |
| 04/05/2000 | EP0990440A1 Drug composition |
| 04/05/2000 | EP0990438A1 Heat stable antacid and antigas suspensions |
| 04/05/2000 | EP0990437A1 Aerosol compositions |
| 04/05/2000 | EP0989957A1 Improved method for preparing low-concentration polyaluminosilicate microgels |
| 04/05/2000 | EP0989906A1 Surfactant compositions |
| 04/05/2000 | EP0989864A1 Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs |
| 04/05/2000 | EP0989857A1 Novel therapeutic agents that modulate enzymatic processes |
| 04/05/2000 | EP0989851A1 Self-emulsifying formulation for acidic lipophilic compounds |
| 04/05/2000 | EP0989849A2 Therapeutic nanospheres |
| 04/05/2000 | EP0989848A2 Film-coated tablet for improved upper gastrointestinal tract safety |
| 04/05/2000 | EP0989847A1 Anti-tumoral therapy agent |
| 04/05/2000 | EP0989846A2 Non-irritating cosmetic and pharmaceutical compositions |
| 04/05/2000 | EP0777740B1 Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle |
| 04/05/2000 | EP0777739B1 Genetic therapy of vascular diseases with a cell-specific active substance which is dependent on the cell cycle |
| 04/05/2000 | EP0734371B1 Novel retinoid conjugate compounds and methods for treating skin aging |
| 04/05/2000 | EP0733072B1 Antibody against carcinoembryonic antigen (cea) |
| 04/05/2000 | EP0605477B1 Gaseous ultrasound contrast media |
| 04/05/2000 | CN1249691A Immobilized activity stabilized LHRH-antagonist complexes, method for production thereof |
| 04/05/2000 | CN1249687A Compositions and methods for reducing ocular hypertension |